Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240913 | 0.88 | ADH5 (0.80) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL246638 | 0.87 | ADH5 (0.79) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL245189 | 0.86 | ADH5 (0.78) | ADH5CYP2C19MAPTPOLBTP53 | |
| N6022 SCHEMBL244480 | 0.86 | ADH5 (1.00) | ADH5CYP2C19MAPTPOLBTP53 | |
| N6022 SCHEMBL29502874 | 0.86 | ADH5 (1.00) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL245000 | 0.83 | ADH5 (0.74) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL243967 | 0.82 | ADH5 (0.72) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL1836093 | 0.82 | ADH5 (0.72) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL1836094 | 0.82 | ADH5 (0.72) | ADH5CYP2C19MAPTPOLBTP53 | |
| SCHEMBL244714 | 0.80 | ADH5 (0.69) | ADH5CYP2C19MAPTPOLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667616-B2 | Oral GSNOR inhibitor and pharmaceutical use thereof | NANJING MEDICAL UNIVERSITY (CN) | 2023-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667616-B2 | Oral GSNOR inhibitor and pharmaceutical use thereof | GSR, GPR119, SLC2A2 | ADH5 3333/4885CYP2C19 1183/4885MAPT 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.